NVRO 250117 22.50P (NVRO250117P22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

NVRO250117P22500

Watchlist

0.00
0.000.00%

15min DelayClose Jan 17 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Citi Maintains Nevro(NVRO.US) With Hold Rating
Moomoo NewsJan 17 06:31 ET · Ratings
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand
Zacks Jan 15 12:00 ET
Nevro | 8-K: Nevro Announces Preliminary Fourth-Quarterand Full-Year 2024 Revenue Results
SECJan 14 12:32 ET · Announcements
CCORF Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4
Moomoo NewsJan 14 07:36 ET · Ratings
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating
Moomoo NewsJan 14 07:36 ET · Ratings
Truist Financial Reaffirms Their Hold Rating on Nevro Corp (NVRO)
TipRanksJan 14 07:18 ET · Ratings

Comments

Trytosaveabit

Nov 12, 2024 06:07

Update

$Nevro (NVRO.US)$ Reuters
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally

Stock_Drift

Nov 11, 2024 16:19

After Hours Ticks. 5:18pm

$Impact BioMedical (IBO.US)$ $Adicet Bio (ACET.US)$ $Zoomcar Holdings (ZCAR.US)$ $Ryde Group (RYDE.US)$ $Foresight Autonomous (FRSX.US)$ $Check-Cap (CHEK.US)$ $Nvni Group (NVNI.US)$ $Bridger Aerospace (BAER.US)$ $Taoping (TAOP.US)$ $Scienjoy (SJ.US)$ $Nevro (NVRO.US)$ $Taysha Gene Therapies (TSHA.US)$ $MultiMetaVerse (MMV.US)$ $XBP Europe Holdings (XBP.US)$

Jaguar8

Sep 24, 2024 07:02

NEWS

$Nevro (NVRO.US)$
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...

Newbee4

Aug 8, 2024 06:22

Do you have any thoughts on this?

$Nevro (NVRO.US)$ @Trytosaveabit

Moomoo AI

Feb 25, 2024 07:35

Nevro's low P/S ratio may be due to its poor revenue outlook. Shareholders accept this as they anticipate no future revenue surprises. These conditions could continue to limit the share price.

Benign Growth For Nevro Corp. (NYSE:NVRO) Underpins Its Share Price